Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2020 | Essential thrombocythemia: outcomes, unmet needs, and therapeutic strategies

Prithviraj Bose • 18 Aug 2020
Texas MPN Workshop 2020
Essential Thrombocythemia Myeloproliferative Neoplasms Rare Diseases Hydroxyurea Imetelstat Ropeginterferon alfa-2b Ruxolitinib Venetoclax Vorinostat

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of disease outcomes, unmet needs and therapeutic strategies of patients with essential thrombocytopenia, including diagnosis, prognosis and management of the disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Prithviraj Bose

The current and emerging therapies for systemic mastocytosis 3:57
The current and emerging therapies for systemic mastocytosis
Prithviraj Bose • 22 Aug 2025
Therapeutic strategies under investigation for treating patients with myelofibrosis and anemia 3:27
Therapeutic strategies under investigation for treating patients with myelofibrosis and anemia
Prithviraj Bose • 22 Aug 2025
Sequencing pacritinib relative to other JAK inhibitors in MF and transitioning from ruxolitinib 3:07
Sequencing pacritinib relative to other JAK inhibitors in MF and transitioning from ruxolitinib
Prithviraj Bose • 22 Aug 2025
The role of pacritinib in the treatment of myelofibrosis 2:51
The role of pacritinib in the treatment of myelofibrosis
Prithviraj Bose • 22 Aug 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals